Study guide

6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

Key Takeaways Explain This Topic AI

Fibrinolysis degrades crosslinked fibrin clots via the serine protease Plasmin; cleavage of Factor XIIIa-crosslinked fibrin uniquely generates D-Dimer fragments, distinguishing true crosslinked fibrin breakdown from primary fibrinogenolysis.

Antithrombin (AT) is a serpin that irreversibly inhibits Thrombin (IIa), FXa, FIXa, FXIa, and FXIIa; binding to the pentasaccharide sequence of unfractionated heparin or LMWH accelerates its inhibitory rate by 1,000-fold.

The Protein C pathway is initiated when thrombin binds endothelial Thrombomodulin; Activated Protein C (APC) complexes with cofactor Protein S to proteolytically inactivate Factor Va and Factor VIIIa.

Factor V Leiden (FV G1691A / Arg506Gln) destroys the APC cleavage site on Factor Va, conferring Activated Protein C Resistance (APCR) and representing the most common hereditary thrombophilia in Caucasians.

Lupus Anticoagulant (LA) is an acquired autoimmune thrombophilia that paradoxically prolongs phospholipid-dependent in vitro clotting times (aPTT, dRVVT) but promotes widespread arterial and venous thrombosis in vivo.

Last updated: August 2026

Fibrinolytic System, Natural Anticoagulants & Thrombophilia

Hemostasis is governed by a dynamic, exquisitely balanced equilibrium between procoagulant forces (driving clot formation to prevent hemorrhage) and anticoagulant/fibrinolytic mechanisms (restricting clot propagation and dissolving fibrin to maintain vascular patency). Disruption of this physiological balance toward excessive clot formation results in thrombophilia (hypercoagulability), predisposing patients to life-threatening venous thromboembolism (VTE) and arterial thrombosis.

The Fibrinolytic System: Biochemistry & Regulation

Fibrinolysis is the enzymatic dissolution of the fibrin clot during wound healing. It is catalyzed by the serine protease Plasmin , which circulates as the inactive liver-synthesized proenzyme Plasminogen . [ FIBRINOLYTIC SYSTEM ]

  • Endothelial Release of t-PA Renal / Tissue u-PA
  • │ │
  • └───────────────────────┬────────────────────────┘
  • │
  • PAI-1 (Inhibits) ──► ▼
  • [ PLASMINOGEN ]
  • │
  • ▼ (Cleavage at Arg561-Val562)
  • [ PLASMIN ] ◄── α2-Antiplasmin (Inactivates Free Plasmin)
  • │
  • ┌───────────────────────────┴───────────────────────────┐
  • ▼ ▼
  • [ CROSSLINKED FIBRIN ] [ FIBRINOGEN (Native) ]
  • │ │
  • ▼ ▼
  • [ D-DIMER FRAGMENTS ] [ FDPs: FRAGMENTS X, Y, D, E ]
  • (Specific Marker of DIC, DVT, PE) (No D-Dimer; Primary Fibrinogenolysis)
  • 1. Plasminogen Activation & Localization

Plasminogen Structure: A 92-kDa single-chain glycoprotein containing five kringle domains . These kringle domains possess high-affinity lysine-binding sites that bind lysine residues on fibrin polymers, incorporating plasminogen directly into the developing clot matrix.

Tissue Plasminogen Activator (t-PA): Synthesized and constitutively released by vascular endothelial cells. t-PA has low enzymatic activity in circulating blood but undergoes a dramatic 1,000-fold increase in catalytic efficiency upon binding fibrin. This ensures that plasmin generation is strictly confined to the fibrin clot surface rather than occurring free in circulating plasma.

Urokinase-type Plasminogen Activator (u-PA): Synthesized by renal tubular epithelium, monocytes, and endothelial cells; lacks high fibrin specificity and operates primarily in pericellular tissue remodeling and extravascular fibrinolysis.

2. Actions of Plasmin: FDPs vs. D-Dimer

Plasmin is a broad-specificity serine protease that cleaves multiple peptide targets:

Degradation of Native Fibrinogen (Primary Fibrinogenolysis): Plasmin sequentially cleaves the carboxy-terminal ends of the A α A\alpha A α and B β B\beta Bβ chains of native fibrinogen. Digestion proceeds through Fragment X (central E domain with two intact D domains), Fragment Y (one D domain and one E domain), and finally terminal Fragment D and Fragment E . These circulating fragments are termed Fibrinogen Degradation Products (FDPs) . FDPs exert potent anticoagulant effects by competing with fibrinogen for thrombin binding and blocking platelet GPIIb/IIIa receptors.

Degradation of Factor XIIIa-Crosslinked Fibrin (Secondary Fibrinolysis): When plasmin degrades a mature, crosslinked fibrin clot, the covalent ε \varepsilon ε -( γ \gamma γ -glutamyl)-lysine bonds connecting adjacent D domains resist cleavage. Plasmin liberates D-Dimer fragments (specifically, two covalently crosslinked D domains bonded to a central E domain, or free D - D D\text{-}D D - D dimers).

Critical Diagnostic Distinction:

D-Dimer: Elevated exclusively when thrombin has converted fibrinogen to fibrin, Factor XIIIa has crosslinked the fibrin, and plasmin has degraded the crosslinked clot . D-Dimer is markedly elevated in Deep Vein Thrombosis (DVT) , Pulmonary Embolism (PE) , and Disseminated Intravascular Coagulation (DIC) .

Primary Fibrinogenolysis: Occurs in systemic hyperplasmin states (e.g., severe hepatic cirrhosis, prostatic carcinoma surgeries releasing urokinase). Plasmin degrades uncrosslinked circulating fibrinogen and Factor V/VIII: FDPs are elevated, but D-Dimer is strictly NORMAL / NEGATIVE .

3. Fibrinolytic Inhibitors

Plasminogen Activator Inhibitor-1 (PAI-1): A serpin secreted by endothelial cells, platelets, and adipose tissue that binds and inactivates t-PA and u-PA in a 1:1 stoichiometric complex.

Alpha-2-Antiplasmin ( α 2 \alpha_2 α 2 ​ -AP): The primary, fast-acting physiological inhibitor of plasmin. It rapidly forms an irreversible, inactive complex with any free plasmin that escapes the fibrin clot into circulating plasma, preventing systemic lytic degradation of circulating fibrinogen and factors.

Thrombin-Activatable Fibrinolysis Inhibitor (TAFI): A plasma carboxypeptidase activated by the thrombin-thrombomodulin complex. TAFI removes carboxy-terminal lysine and arginine residues from partially degraded fibrin, eliminating high-affinity binding sites for plasminogen and t-PA and attenuating clot lysis.

Natural Anticoagulant Systems

To prevent unchecked propagation of thrombosis beyond the site of vascular injury, the vascular system relies on three major natural anticoagulant pathways: [ NATURAL ANTICOAGULANT PATHWAYS ]

  • 1. ANTITHROMBIN (AT) ──► Inhibits Thrombin (IIa), FXa, FIXa, FXIa, FXIIa
  • ▲
  • └── Heparan Sulfate / Heparin (Accelerates AT Activity by 1,000-fold)
  • 2. PROTEIN C / PROTEIN S PATHWAY
  • Thrombin + Endothelial Thrombomodulin ──► Activates Protein C (APC)
  • │
  • APC + Free Protein S (Cofactor) ◄────────────────┘
  • │
  • ▼ (Targeted Proteolytic Inactivation)
  • Factor Va ──► FVa Inactivated (Cleaved at Arg506 / Arg306)
  • Factor VIIIa ──► FVIIIa Inactivated (Cleaved at Arg336 / Arg562)
  • 3. TISSUE FACTOR PATHWAY INHIBITOR (TFPI)
  • TFPI binds Factor Xa ──► TFPI:FXa Complex binds & inactivates TF:FVIIa
  • 1. The Antithrombin (AT) Pathway

Mechanism: Antithrombin (formerly ATIII) is a 58-kDa serine protease inhibitor ( serpin ) synthesized by hepatocytes. It forms stable, irreversible covalent suicide complexes with the active serine center of Thrombin (Factor IIa) , Factor Xa , Factor IXa , Factor XIa , and Factor XIIa .

Heparin Acceleration: In the baseline uncatalyzed state, AT neutralizes target proteases relatively slowly. Vascular endothelial cell-surface heparan sulfate proteoglycans (and exogenous unfractionated heparin / LMWH) contain a unique high-affinity pentasaccharide sequence . Binding of this pentasaccharide to AT induces an allosteric conformational shift (expelling the reactive center loop), accelerating the rate of Factor Xa and thrombin inactivation by 1,000-fold .

2. The Protein C & Protein S Anticoagulant Pathway

Thrombomodulin Reversal of Thrombin: Vascular endothelial cells express Thrombomodulin (TM) , an integral transmembrane glycoprotein. Circulating thrombin binds TM with high affinity ( K d ≈ 0.5 nmol/L K_d \approx 0.5\text{ nmol/L} K d ​ ≈ 0.5 nmol/L ). This binding alters thrombin's active site conformation: thrombin loses its procoagulant properties (can no longer cleave fibrinogen or activate platelets) and converts into an activator of Protein C .

Endothelial Protein C Receptor (EPCR): EPCR presents the vitamin K-dependent zymogen Protein C to the thrombin-TM complex, accelerating its cleavage to Activated Protein C (APC) .

Inactivation of Factors Va and VIIIa: APC dissociates from EPCR and binds its vitamin K-dependent cofactor Protein S on negatively charged phospholipid membranes. The APC:Protein S complex proteolytically cleaves the heavy chains of Factor Va (at Arg506 and Arg306) and Factor VIIIa (at Arg336 and Arg562), completely dismantling the prothrombinase and intrinsic tenase complexes.

Protein S Binding Dynamics: In human plasma, Protein S circulates in two distinct forms:

Free Protein S (~40%): The functionally active cofactor for APC.

Bound Protein S (~60%): Complexed to the complement regulatory protein C4b-Binding Protein (C4b-BP) ; functionally inactive.

Inflammatory State Impact: C4b-BP is an acute-phase reactant. In severe systemic inflammation, elevated C4b-BP binds more Protein S, reducing free active Protein S and inducing an acquired hypercoagulable state.

3. Tissue Factor Pathway Inhibitor (TFPI)

Synthesized primarily by microvascular endothelial cells (circulating bound to lipoproteins and stored in endothelial surfaces and platelets). It contains three tandem Kunitz-type inhibitory domains :

Kunitz-2 domain binds and inhibits Factor Xa .

The resulting TFPI:FXa complex utilizes its Kunitz-1 domain to bind and feedback-inhibit the TF:FVIIa complex , completely turning off the extrinsic initiation of coagulation.

Hereditary Thrombophilias

Thrombophilia Condition Genetic Mutation / Molecular Defect Population Prevalence & Relative VTE Risk Pathophysiologic Mechanism Diagnostic Testing Protocol

Factor V Leiden (FVL) Point mutation in Factor V gene: c .1691 G > A c.1691\text{G}>\text{A} c .1691 G > A , causing an Arg506Gln \text{Arg506Gln} Arg506Gln amino acid substitution. Most common hereditary thrombophilia (~5% in Caucasians; rare in Asian/African lineages). Heterozygotes: 4–8x VTE risk ; Homozygotes: 50–80x VTE risk . The Arg506 cleavage site for Activated Protein C is destroyed. Factor Va remains resistant to APC proteolytic inactivation (Activated Protein C Resistance - APCR) , causing sustained prothrombinase activity. Screening: Clot-based APCR assay (ratio of aPTT with APC to baseline aPTT; ratio < 2.0 <2.0 < 2.0 indicates APCR).; Confirmation: PCR DNA molecular genotyping for F V G1691A FV\text{ G1691A} F V G1691A .

Prothrombin G20210A Mutation Point mutation in the 3 ′ 3' 3 ′ -untranslated region ( 3 ′ -UTR 3'\text{-UTR} 3 ′ -UTR ) of the prothrombin ( F2 ) gene: c . ∗ 97 G > A c.*97\text{G}>\text{A} c . ∗ 97 G > A ( G 20210 A G20210A G 20210 A ) . Second most common inherited thrombophilia (~2–3% in Caucasians). Heterozygotes: 2–3x VTE risk . Mutation enhances 3 ′ 3' 3 ′ -end mRNA processing, polyadenylation, and translational efficiency, causing elevated plasma prothrombin levels (>130%) and excessive thrombin generation. Definitive: PCR DNA molecular testing for the F2 G20210A mutation (plasma prothrombin antigen is non-specific).

Antithrombin Deficiency Hereditary autosomal dominant mutations in SERPINC1 gene. Type I (quantitative, low antigen + low activity); Type II (qualitative, normal antigen, low activity). Rare (~0.02% general, 1–2% VTE cohorts); Highest thrombotic risk (20–50x VTE risk) ; spontaneous VTE in young adults. Inability to neutralize thrombin and Factor Xa; heparin resistance (inability to achieve therapeutic aPTT despite high-dose heparin). Functional chromogenic anti-FXa / anti-FIIa assay (measures AT activity in the presence of excess heparin).

Protein C Deficiency Hereditary autosomal dominant mutations in PROC gene. Type I (quantitative); Type II (qualitative). ~0.2% general population; 5–10x VTE risk . Impaired proteolytic cleavage and down-regulation of Factors Va and VIIIa. Warfarin-Induced Skin Necrosis: Rapid drop in short-half-life Protein C upon initiating warfarin creates transient severe prothrombotic state. Functional chromogenic or clot-based Protein C activity assay ; antigenic ELISA for typing.

Protein S Deficiency Hereditary autosomal dominant mutations in PROS1 gene. Type I (low total and free antigen, low activity); Type II (normal antigen, low activity); Type III (normal total antigen, low free antigen and activity). ~0.1–0.2% general population; 5–10x VTE risk . Impaired cofactor function for APC, failing to suppress FVa and FVIIIa. Free Protein S antigenic assay (immunoturbidimetric / ELISA) and functional clot-based assay.

Acquired Thrombophilias: Antiphospholipid Syndrome (APS) & Lupus Anticoagulant

Antiphospholipid Syndrome (APS) is an acquired autoimmune multisystem disorder characterized by arterial and/or venous thrombosis and pregnancy morbidity (recurrent spontaneous miscarriages, fetal demise, severe preeclampsia) in the presence of persistent antiphospholipid antibodies (aPL) .

The Three Diagnostic Antiphospholipid Antibodies

Per the revised Sapporo / Sydney international diagnostic criteria, at least one laboratory criterion must be positive on two or more occasions tested at least 12 weeks apart :

Lupus Anticoagulant (LA): Functional clot-based antibodies that interfere with phospholipid-dependent coagulation tests.

Anticardiolipin Antibodies (aCL): Solid-phase immunoassay (ELISA / chemiluminescence) detecting IgG or IgM isotypes at medium-to-high titers ( > 40 GPL or MPL units >40\text{ GPL or MPL units} > 40 GPL or MPL units ).

Anti- β 2 \beta_2 β 2 ​ -Glycoprotein I Antibodies (anti- β 2 \beta_2 β 2 ​ GPI): Solid-phase immunoassay detecting IgG or IgM directed against the domain I epitope of β 2 GPI \beta_2\text{GPI} β 2 ​ GPI .

The Lupus Anticoagulant Laboratory Paradox & Three-Step Testing Protocol

The In Vitro vs. In Vivo Paradox:

In Vitro (The Artifact): LA autoantibodies bind to phospholipid-protein complexes (such as β 2 GPI \beta_2\text{GPI} β 2 ​ GPI and prothrombin) in the test tube, sterically hindering the assembly of tenase and prothrombinase complexes on reagent phospholipids. This causes paradoxical prolongation of phospholipid-dependent clotting tests (aPTT, Dilute Russell's Viper Venom Time [dRVVT]) .

In Vivo (The Pathology): In the patient, LA antibodies crosslink receptors on endothelial cells, platelets, and monocytes, inducing pro-inflammatory and prothrombotic signaling that drives severe venous and arterial thrombosis . [ LUPUS ANTICOAGULANT 3-STEP PROTOCOL ]

  • STEP 1: SCREENING TEST
  • Perform low-phospholipid clotting assay (dRVVT Screen or LA-sensitive aPTT)
  • Result: PROLONGED CLOTTING TIME (suggests presence of inhibitor)
  • │
  • ▼
  • STEP 2: 1:1 MIXING STUDY
  • Mix Patient Plasma 1:1 with Normal Pooled Plasma (NPP)
  • Result: NO CORRECTION (Clotting time remains prolonged ──► Demonstrates Inhibitor, rules out factor deficiency)
  • │
  • ▼
  • STEP 3: CONFIRMATORY TEST
  • Repeat assay in the presence of EXCESS PHOSPHOLIPIDS (Bilayer liposomes, Platelet Lysate, Hexagonal-phase PE)

• Result: COMPLETE CORRECTION / SHORTENING OF CLOTTING TIME

• Principle: Excess phospholipids neutralize circulating LA autoantibodies, confirming PHOSPHOLIPID DEPENDENCE.

Dilute Russell's Viper Venom Time (dRVVT): The gold-standard assay for Lupus Anticoagulant testing because venom from Daboia russelii directly activates Factor X in the presence of C a 2 + Ca^{2+} C a 2 + and phospholipids, completely bypassing Factors XII, XI, IX, VIII, and VII (rendering the test immune to intrinsic pathway factor deficiencies or contact factor inhibitors).